TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32390724

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 34
Study: 35288248

Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure therapy (ciNPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 35088602

Group type: EXPERIMENTAL
Intervention: Combined early palliative care (CEPC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard oncological care (SC)
Number of subjects: 120
Study: 33270306

Group type: EXPERIMENTAL
Intervention: VASCADE® venous vascular closure system (VVCS)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: No urinary catheter (UC)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Heparin without protamine reversal
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Same calendar day discharge (SCDD)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 168
Study: 32715449

Group type: EXPERIMENTAL
Intervention: Thulium laser
Number of subjects: 35

Group type: COMPARATOR
Intervention: Monopolar TURBT
Number of subjects: 35
Study: 32703098

Group type: EXPERIMENTAL
Intervention: Algorithm-practice (hybrid practice schedule with forward/backward switching based on error trial number)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blocked-practice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Random-practice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dissimilar conditions (blocked, algorithm, random)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Similar conditions (blocked, algorithm, random)
Number of subjects: 60
Study: 36170895

Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care pathway
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with 30% drug discount
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with 60% drug discount
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with 90% drug discount
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with re-infection rates of 8/5/2 per 100 person-years
Number of subjects: 0
Study: 34086176

Group type: EXPERIMENTAL
Intervention: Exposure to indoor air pollutants (PM2.5, CO, BC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Biomass used for cooking
Number of subjects: 68
Study: 32599767

Group type: EXPERIMENTAL
Intervention: Internet-based physical activity promotion for 3 months after rehabilitation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Internet-based physical activity promotion
Number of subjects: 64

Group type: COMPARATOR
Intervention: No intervention (Control Group)
Number of subjects: 64
Study: 34578798

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with monosodium glutamate (MSG) at 2.7 g/day during the second round of chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no MSG supplementation)
Number of subjects: 0
Study: 33051035

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Countering emotional behaviors
Number of subjects: 5
Study: 35201806

Group type: EXPERIMENTAL
Intervention: 3-day marijuana deprivation (N = 68)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Continuing heavy marijuana use (N = 66)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Posthoc analyses on startle reactivity × deprivation interaction
Number of subjects: 210
Study: 35769355

Group type: EXPERIMENTAL
Intervention: Lobaplatin (30 mg/m²) added to docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lobaplatin (30 mg/m²) added to docetaxel and epirubicin.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Docetaxel and epirubicin without lobaplatin.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lobaplatin added to chemotherapy.
Number of subjects: 200
Study: 33077331

Group type: EXPERIMENTAL
Intervention: Open fire with biomass fuel for cooking (85.8% of households)
Number of subjects: 2713

Group type: EXPERIMENTAL
Intervention: Households with an older sibling ≥12 years
Number of subjects: 2713

Group type: EXPERIMENTAL
Intervention: Older age of children
Number of subjects: 2713
Study: 616507939

Group type: EXPERIMENTAL
Intervention: UMUST (Unexpected Medical Undergraduate Simulation Training)
Number of subjects: 0
Study: 35462500

Group type: EXPERIMENTAL
Intervention: Time in Range (TIR) with Glycemic Management Indicator (GMI) at a fixed GMI value of 7%
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Lowest quartile of CV (≤35.91%)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 25th-50th quartile of CV (35.91%<CV≤40.08%)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 50th-75th quartile of CV (40.08%<CV≤45.86%)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Highest quartile of CV (>75th quartile, CV>45.86%)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Correlation between TIR and GMI
Number of subjects: 83
Study: 35277067

Group type: EXPERIMENTAL
Intervention: Low-GI MED-HEP
Number of subjects: 160

Group type: COMPARATOR
Intervention: High-GI MED-HEP
Number of subjects: 160
Study: 33693494

Group type: EXPERIMENTAL
Intervention: 5 mg SHR4640
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 10 mg SHR4640
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 50 mg benzbromarone
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 32757339

Group type: EXPERIMENTAL
Intervention: Short waiters (≤ 18 weeks)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Long waiters (> 18 weeks)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Change in waiting time by a week
Number of subjects: 203
Study: 35727844

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided transversus abdominis plane (UTAP)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Robot-assisted transversus abdominis plane (RTAP)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Local anaesthesia (LA)
Number of subjects: 143
Study: 32312313

Group type: EXPERIMENTAL
Intervention: Word version of the manuscript
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: PDF version of the manuscript
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: All journals
Number of subjects: 602
Study: 616501576

Group type: EXPERIMENTAL
Intervention: Common three‐dose intramuscular priming series followed by a final booster at 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Common three‐dose intramuscular priming series followed by a final booster at 12 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both vaccine regimens
Number of subjects: 12
Study: 34824000

Group type: EXPERIMENTAL
Intervention: O2 treatment over the protective face mask
Number of subjects: 40

Group type: COMPARATOR
Intervention: Protective face mask worn over the O2 delivery system
Number of subjects: 40
Study: 33871845

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32669132

Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 33810996

Group type: EXPERIMENTAL
Intervention: Olfactory rehabilitation using four different odors applied orthonasally for 30 min per day for 6 months
Number of subjects: 11
Study: 33160695

Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 203

Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 203
Study: 32913210

Group type: EXPERIMENTAL
Intervention: TAP + LMA
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (General anesthesia with endotracheal intubation)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 36124652

Group type: EXPERIMENTAL
Intervention: Increase in dietary choline intake (Q4)
Number of subjects: 5613

Group type: EXPERIMENTAL
Intervention: Increase in dietary betaine intake (Q4)
Number of subjects: 5613
Study: 35119213

Group type: EXPERIMENTAL
Intervention: Plastic cannulae
Number of subjects: 8

Group type: COMPARATOR
Intervention: Metal needles
Number of subjects: 8
Study: 35912143

Group type: EXPERIMENTAL
Intervention: Gamma globulin combined with azithromycin sequential therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Azithromycin plus comprehensive basic treatment
Number of subjects: 100
Study: 34138667

Group type: EXPERIMENTAL
Intervention: IGF‐1 injections combined with HSR training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline injections combined with HSR training
Number of subjects: 40
Study: 33795978

Group type: EXPERIMENTAL
Intervention: Undiagnosed hypertension
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Undiagnosed type 2 diabetes (T2D)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Both undiagnosed hypertension and undiagnosed T2D
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Undiagnosed T2D
Number of subjects: 378
Study: 32413431

Group type: EXPERIMENTAL
Intervention: Absorbable anchors
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 53
Study: 33583341

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 40 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 33933236

Group type: EXPERIMENTAL
Intervention: CT‐CONT (continuation of first-line fluorouracil/platinum-based chemotherapy)
Number of subjects: 67

Group type: COMPARATOR
Intervention: CT‐DISC (discontinuation of first-line chemotherapy)
Number of subjects: 67
Study: 33336218

Group type: EXPERIMENTAL
Intervention: Gantenerumab 1200 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marguerite RoAD double-blind placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marguerite RoAD double-blind active
Number of subjects: 0
Study: 34657856

Group type: EXPERIMENTAL
Intervention: Robot-assisted trunk control training (RT group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional trunk stabilization training + stretching exercise (Control group)
Number of subjects: 40
Study: 34912120

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus trastuzumab and chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 0
Study: 32723330

Group type: EXPERIMENTAL
Intervention: Emergency obstetric simulation-based training program
Number of subjects: 7
Study: 35094447

Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% after TCA-CROSS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Saline injection before TCA-CROSS
Number of subjects: 45

Group type: COMPARATOR
Intervention: TCA-CROSS alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline + TCA-CROSS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patient satisfaction in groups 2 and 3
Number of subjects: 45
Study: 33625665

Group type: EXPERIMENTAL
Intervention: Caffeine stopped at 7 days apnea-free period
Number of subjects: 120

Group type: COMPARATOR
Intervention: Caffeine continued until at least 34 weeks postmenstrual age (PMA)
Number of subjects: 120
Study: 32513288

Group type: EXPERIMENTAL
Intervention: PK-guided dosage adjustments of docetaxel-based chemotherapy
Number of subjects: 209

Group type: COMPARATOR
Intervention: BSA-guided dosage adjustments of docetaxel-based chemotherapy
Number of subjects: 209
Study: 34725926

Group type: EXPERIMENTAL
Intervention: Youth and family members as full members of the project team, including project leadership and governance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-designed service pathway including peer support and family member intervention as core service components.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth defined the primary outcome measure and contributed to secondary measures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training research staff on working with youth and family members.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth and family members as co-presenters and manuscript co-authors in knowledge translation activities.
Number of subjects: 0
Study: 34631520

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 25
Study: 35313967

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMNCs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Purified CD34+ cells (PCCs)
Number of subjects: 50
Study: 34785589

Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of plaque volume (PV) and calcified plaque (CP) in patients >65 years
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of % percent atheroma volume (%PAV) of low-density non-calcified plaque (LD‐NCP) in patients <65 years
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of plaque characteristics in obstructive vs non-obstructive lesions in younger patients
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of lesion types in older patients
Number of subjects: 303
Study: 33461782

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1538
Study: 32942627

Group type: EXPERIMENTAL
Intervention: Personalized Nutrition Advice (PNA)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Personalized Nutrition Advice (PNA) with goal-setting
Number of subjects: 155

Group type: COMPARATOR
Intervention: Generic Nutrition Advice (GNA)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no advice)
Number of subjects: 155
Study: 32576079

Group type: EXPERIMENTAL
Intervention: Practical experiential training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional lecture teaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without safety/health education and training)
Number of subjects: 0
Study: 33546949

Group type: EXPERIMENTAL
Intervention: 2008–2012 salt intake
Number of subjects: 3844

Group type: EXPERIMENTAL
Intervention: 2018–2019 salt intake
Number of subjects: 3844

Group type: COMPARATOR
Intervention: Salt intake reduction
Number of subjects: 3844
Study: 32290072

Group type: EXPERIMENTAL
Intervention: Active Plus intervention
Number of subjects: 260
Study: 36239290

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 32215700

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Irbesartan (adjusted for baseline variables)
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1505
Study: 35796651

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin plus saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment plus GIP(3‐30)NH2
Number of subjects: 12
Study: 33772963

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of antihaemophilic factor (recombinant)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bolus infusion (BI) of antihaemophilic factor (recombinant)
Number of subjects: 60
Study: 32762701

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 96
Study: 36180143

Group type: EXPERIMENTAL
Intervention: Three-part breathing exercise plus counseling for smoking cessation once a week for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Counseling for smoking cessation once a week for 12 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Three-part breathing exercise plus counseling for smoking cessation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Counseling for smoking cessation
Number of subjects: 43
Study: 33844358

Group type: EXPERIMENTAL
Intervention: 3v3 small-sided games
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) scores
Number of subjects: 0
Study: 33629758

Group type: EXPERIMENTAL
Intervention: Immigrant‐origin youth
Number of subjects: 179

Group type: COMPARATOR
Intervention: Non‐immigrant‐origin youth
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Active bystander responses
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Bystander responses to bullying and retaliation
Number of subjects: 179
Study: 36360995

Group type: EXPERIMENTAL
Intervention: Online supervised exercise program (from 8‐10 to 38‐39 weeks of pregnancy)
Number of subjects: 260
Study: 33459481

Group type: EXPERIMENTAL
Intervention: Ward round checklist
Number of subjects: 124
Study: 32800532

Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg IV infused over 60 min
Number of subjects: 34
Study: 35768101

Group type: EXPERIMENTAL
Intervention: Whole-body photobiomodulation therapy (NovoTHOR)
Number of subjects: 20
Study: 34812070

Group type: EXPERIMENTAL
Intervention: Intensive multiplanar trunk training coupled with dual-task exercises
Number of subjects: 74
Study: 32343890

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control (enzalutamide or abiraterone)
Number of subjects: 245
Study: 35088753

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Citalopram (40 mg/d for 12 weeks)
Number of subjects: 107
Study: 34111071

Group type: EXPERIMENTAL
Intervention: Responsive stimulation and nutrition interventions
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: 6-item motor composite of the Brief Form of Bruininks Oseretsky Test
Number of subjects: 1058
Study: 32588194

Group type: EXPERIMENTAL
Intervention: Alternating (ALT) BFR exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unilateral (UNI) BFR exercise
Number of subjects: 20
Study: 36331522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.5 mg empagliflozin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin
Number of subjects: 24
Study: 33086400

Group type: EXPERIMENTAL
Intervention: Emicizumab 1.5 mg/kg once-weekly subcutaneous
Number of subjects: 112
Study: 32389606

Group type: EXPERIMENTAL
Intervention: Goal-concordant care
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Goal-discordant care
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Uncertain focus of care
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Goal-concordant care for patients prioritizing extending life
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Goal-discordant care for patients prioritizing extending life
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Uncertain focus of care for patients prioritizing extending life
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Goal-concordant care for patients prioritizing relief of pain and discomfort
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Goal-discordant care for patients prioritizing relief of pain and discomfort
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Uncertain focus of care for patients prioritizing relief of pain and discomfort
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Relative risk of goal-discordant care for patients prioritizing relief of pain and discomfort vs extending life
Number of subjects: 405
Study: 35446293

Group type: EXPERIMENTAL
Intervention: TPDLP (transperineal pelvic drainage combined with lateral position)
Number of subjects: 60

Group type: COMPARATOR
Intervention: N-TPDLP (standard arm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TPDLP
Number of subjects: 60

Group type: COMPARATOR
Intervention: N-TPDLP
Number of subjects: 60
Study: 33541372

Group type: EXPERIMENTAL
Intervention: Nourish
Number of subjects: 903

Group type: COMPARATOR
Intervention: Control (Delayed)
Number of subjects: 903
Study: 32758038

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (0.1 mmol·kg‐1·day‐1)
Number of subjects: 30
Study: 35742698

Group type: EXPERIMENTAL
Intervention: 4.5% nicotine EC
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (0% nicotine) EC
Number of subjects: 84
Study: 33025405

Group type: EXPERIMENTAL
Intervention: Overlap group (AACGN + ICMGN)
Number of subjects: 29

Group type: COMPARATOR
Intervention: AACGN-only group
Number of subjects: 29
Study: 32672670

Group type: EXPERIMENTAL
Intervention: MINIject (iSTAR Medical, Wavre, Belgium)
Number of subjects: 26
Study: 35747192

Group type: EXPERIMENTAL
Intervention: TMZ-MBZ (Temozolomide + Mebendazole)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CCNU-MBZ (Lomustine + Mebendazole)
Number of subjects: 88
Study: 33733311

Group type: EXPERIMENTAL
Intervention: Individualized-Targeted Cognitive Training
Number of subjects: 88

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 88
Study: 32624473

Group type: EXPERIMENTAL
Intervention: Tai Chi Cardiac Rehabilitation Program (TCCRP) supervised three times a week for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional exercise rehabilitation supervised three times a week for 3 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tai Chi Cardiac Rehabilitation Program (TCCRP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional exercise rehabilitation
Number of subjects: 150
Study: 35543853

Group type: EXPERIMENTAL
Intervention: IVB + normal vitamin D levels (Group 1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: IVB + vitamin D insufficient/deficient (Group 2)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: IVB + vitamin D insufficient/deficient + oral vitamin D supplementation (Group 3)
Number of subjects: 83
Study: 33227785

Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Therapy (PFPP)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Choice and Random Conditions
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control Group (Waiting List)
Number of subjects: 221
Study: 34922058

Group type: EXPERIMENTAL
Intervention: ceftaroline fosamil
Number of subjects: 1976

Group type: COMPARATOR
Intervention: comparator
Number of subjects: 1976